- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04216641
Cancer, Nutrition and Taste (CANUT-1)
Impact of a Food Improvement Strategy on Their Appreciation in a Population of Cancer Patients Treated With Chemotherapy
Cancer promotes weight loss; it can also lead to particular complications for patients during treatment. A team led by Dr Michael Sawyer, showed the deleterious impact of undernutrition on the benefits of chemotherapy.
Cancer patients are at high risk of undernutrition, which is generally more pronounced for solid tumours (upper digestive tract, ENT, bronchial tubes…). This undernutrition leads to major weight loss and wasting, and may represent the first sign of a call for a diagnosis of cancer. Cancer-related undernutrition is multi-factorial in origin and has multiple consequences; it has its own prognostic value.
Chemotherapy treatments can induce various adverse effects in patients, including sensory disturbances at the beginning of treatment in addition to disturbances that may already be present before any treatment. Altered taste and odour, observed in 86% of patients, can induce a change in food preferences, promote the development of aversions, and therefore, lead to a significant reduction in the pleasure of eating. Loss of appetite, decreased food intake and the development of aversions to certain foods are situations experienced by a large proportion of patients undergoing chemotherapy.
The assessment of taste disorders in patients undergoing chemotherapy treatment is established through the use of questionnaires, interviews and taste tests.
Changes in the perception and identification of salty, sweet, bitter and sour flavours are common in patients undergoing chemotherapy.
The objective of CANUT is to study the effect of pathology and chemotherapy on gustatory and olfactory mechanisms and in particular on interindividual differences in the perception and appreciation of food.
In this study the investigators propose to adapt foods to best respond to sensory disorders related to the disease and/or treatment.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: David DAYDE, manager
- Phone Number: +33 +33.4.78.86.37.74
- Email: david.dayde@chu-lyon.fr
Study Contact Backup
- Name: Nadjat MEDEGHRI, manager
- Phone Number: +33 +33.4.78.86.37.74
- Email: nadjat.medeghri@chu-lyon.fr
Study Locations
-
-
-
Bron, France, 69677
- Hôpital Louis Pradel
-
Lyon, France, 69008
- Centre Leon Berard
-
Lyon, France, 69004
- Hôpital de jour - Hôpital de la Croix Rousse
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patient with advanced lung cancer requiring a first line of intravenous chemotherapy or patient with localized, histologically or cytologically proven breast cancer for whom intravenous chemotherapy treatment will be initiated or patient with stage III-IV gynecological cancer (ovarian cancer or uterine cancer) for whom intravenous chemotherapy treatment will be initiated.
- Patient with a body mass index (BMI) between 18Kg/m² and 35Kg/m².
- Patient whose indication for treatment with intravenous chemotherapy has been selected
- Naive patient of previous chemotherapy.
- Life expectancy > 3 months.
- Patient able to travel for 4 visits to the Paul Bocuse Institute, 1 Chemin de Calabert, 69 130 ECULLY, FRANCE.
- Written informed consent obtained in accordance with applicable GCPs.
- Patients affiliated to a social security system.
- Patients who have the possibility of being accompanied, by the same person, to the visits of the test meals at the Paul Bocuse Research Institute
Exclusion Criteria:
- Patient under 18 years of age.
- Patient who has had another malignant tumor in the last 3 years.
- Patient with symptomatic brain metastases.
- Patient with symptomatic mucositis.
- Patient suffering or having suffered from an otorhinolaryngic or oesogastrointestinal pathology interfering with food intake.
- Patients with digestive disorders before any cancer treatment.
- Indication for concomitant radiotherapy or immunotherapy alone treatment.
- Patient with a known food allergy or food intolerance.
- Patient with partial or total agueusia diagnosed.
- Patient with diagnosed partial or total anosmia.
- Patients who have used artificial feeding within 2 months.
- Patients who have lost more than 10% of their baseline weight within 2 months.
- Patient unable to be regularly monitored for any reason
- Patient deprived of liberty or placed under guardianship or curatorship
- Pregnant or breastfeeding patient.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention arm
At each meal: different elements will be presented to the patient (starter / main course / side dish / dessert). For each of these elements, the patient will be offered 4 versions (a standard version and 3 adapted versions of the same food):
The patient will indicate the version of the food that will be preferred. |
Adapted food intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
proportion of treated patients by 4 cycles of chimiotherapy that will prefere at least 1 modified version of meal.
Time Frame: 12 weeks
|
The main endpoint of the CANUT-1 study is the proportion of cancer patients treated with chemotherapy (after 4 cycles) who will prefer at least an adapted version of a food compared to the standard version of the same food.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Food assessment scores ( 0/4 to 4/4, 4 mean a better score)
Time Frame: Before Cycle 1(each cycle is 28 days) of chemotherapy treatment
|
Individual food assessment scores (standard food and adapted food to taste and smell disorders) before any treatment
|
Before Cycle 1(each cycle is 28 days) of chemotherapy treatment
|
Food assessment scores ( 0/4 to 4/4,4 mean a better score)
Time Frame: after 2 cycles (each cycle is 28 days) of chemotherapy
|
: Individual food assessment scores (standard food and adapted food to taste and smell disorders) after 2 cycles of chemotherapy
|
after 2 cycles (each cycle is 28 days) of chemotherapy
|
Food assessment scores ( 0/4 to 4/4, 4 mean a better score)
Time Frame: after 4 cycles(each cycle is 28 days) of chemotherapy
|
: Individual food assessment scores (standard food and adapted food to taste and smell disorders) after 4 cycles of chemotherapy
|
after 4 cycles(each cycle is 28 days) of chemotherapy
|
European Test of Olfactory Capabilities (ETOC) (1 (mean a worse) to 9 (mean a better)
Time Frame: Before cycle 1(each cycle is 28 days) of chemotherapy treatment
|
The results of olfactory detection and identification, familiarity, pleasantness, intensity, edibility and trigeminal perception (fresh, hot, irritant, pungent) European Test of Olfactory Capabilities (ETOC) before any treatment, after 2 and 4 cycles of chemotherapy. The results of olfactory detection and identification, familiarity, pleasantness, intensity, edibility and trigeminal perception (fresh, hot, irritant, pungent) European Test of Olfactory Capabilities (ETOC) before any treatment |
Before cycle 1(each cycle is 28 days) of chemotherapy treatment
|
European Test of Olfactory Capabilities (ETOC)(1 (mean a worse) to 9 (mean a better)
Time Frame: after 2 cycles (each cycle is 28 days) of chemotherapy
|
The results of olfactory detection and identification, familiarity, pleasantness, intensity, edibility and trigeminal perception (fresh, hot, irritant, pungent) European Test of Olfactory Capabilities (ETOC) after 2 of chemotherapy.
|
after 2 cycles (each cycle is 28 days) of chemotherapy
|
European Test of Olfactory Capabilities (ETOC)(1 (mean a worse) to 9 (mean a better)
Time Frame: after 4 cycles(each cycle is 28 days) of chemotherapy
|
The results of olfactory detection and identification, familiarity, pleasantness, intensity, edibility and trigeminal perception (fresh, hot, irritant, pungent) European Test of Olfactory Capabilities (ETOC) after and 4 cycles of chemotherapy.
|
after 4 cycles(each cycle is 28 days) of chemotherapy
|
Condiments consumption assessment by condiments questionnaire (0 contiment to 12 condiments)
Time Frame: Before cycle 1(each cycle is 28 days) of treatment
|
The number of condiments added at the time of inclusion
|
Before cycle 1(each cycle is 28 days) of treatment
|
Condiments consumption assessment by condiments questionnaire (0 contiment to 12 condiments)
Time Frame: after 2 cycles(each cycle is 28 days) of chemotherapy
|
The number of condiments added after 2 cycles of chemotherapy.
|
after 2 cycles(each cycle is 28 days) of chemotherapy
|
Condiments consumption assessment by condiments questionnaire (0 contiment to 12 condiments)
Time Frame: after 4 cycles(each cycle is 28 days) of chemotherapy
|
The number of condiments added after 4 cycles of chemotherapy.
|
after 4 cycles(each cycle is 28 days) of chemotherapy
|
Food temperature
Time Frame: Before Cycle 1(each cycle is 28 days) of chemotherapy treatment
|
The proportion of patients who prefer to consume cold foods versus those who prefer to consume hot foods at the time of inclusion
|
Before Cycle 1(each cycle is 28 days) of chemotherapy treatment
|
Food temperature
Time Frame: after 2 cycles(each cycle is 28 days) of chemotherapy
|
The proportion of patients who prefer to consume cold foods versus those who prefer to consume hot foods after 2 cycles of chemotherapy
|
after 2 cycles(each cycle is 28 days) of chemotherapy
|
Food temperature
Time Frame: after 4 cycles(each cycle is 28 days) of chemotherapy
|
The proportion of patients who prefer to consume cold foods versus those who prefer to consume hot foods at 4 cycles of chemotherapy
|
after 4 cycles(each cycle is 28 days) of chemotherapy
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 69HCL19_0292
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
Clinical Trials on Adapted food intervention
-
Sarah BlaylockVA Office of Research and DevelopmentCompletedFall | Low VisionUnited States
-
University of Massachusetts, WorcesterHealth Resources and Services Administration (HRSA)CompletedPosttraumatic Stress Disorder
-
Columbia UniversityNational Institute of Mental Health (NIMH)RecruitingSchizophrenia | Schizo Affective Disorder | Delusional Disorder | Schizophreniform Disorders | Other Specified Schizophrenia Spectrum and Other Psychotic DisorderUnited States
-
University of California, Los AngelesNational Institute on Drug Abuse (NIDA); American Academy of Child Adolescent...RecruitingCoping Skills | Family RelationshipUnited States
-
Jennifer Bogner, PhD, ABPPU.S. Department of EducationCompletedTraumatic Brain InjuryUnited States
-
VA Connecticut Healthcare SystemWithdrawnConditions: Serious Mental Illness
-
Penn State UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...Active, not recruitingSleep | Parent-Child Relations | Parenting | Marital RelationshipUnited States
-
The University of Texas Health Science Center at...National Institute on Aging (NIA)Not yet recruitingType 2 DiabetesUnited States
-
University of ConnecticutTerminated
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)Recruiting